Alaunos Therapeutics (TCRT) Assets (2009 - 2026)

Alaunos Therapeutics has reported Assets for 18 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 11.18% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (down 11.18% YoY), and the FY2025 full-year result was $3.0 million, up 7.66% from the prior year.
• Assets for Q1 2026 stood at $1.9 million, down from $3.0 million in the prior quarter.
• The five-year high for Assets was $85.0 million in Q1 2022, with the low at $1.9 million in Q1 2026.
• Historically, Assets has averaged $25.2 million across 5 years, with a median of $6.0 million in 2024.
• Annual changes were most pronounced in 2024 — Assets tumbled 87.59% — and 2025, when it advanced 7.66%.
• Alaunos Therapeutics' Assets stood at $64.9 million in 2022, then plunged by 87.28% to $8.3 million in 2023, then slumped by 66.66% to $2.8 million in 2024, then climbed by 7.66% to $3.0 million in 2025, then sank by 36.51% to $1.9 million in 2026.
• The last three Assets figures came in at $1.9 million (Q1 2026), $3.0 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.